In their hunt for new approvals, biopharma companies spend billions of dollars every year on clinical trials. In recent years, though, real-world studies as sources of practice-informing data––and even as the basis for new indications––have multiplied. but clinical trials remain the gold standard.

In a post-pandemic future, will clinical trials ever look the same again? Could real-world data help fill in the gaps? In this session, we will discuss the role real-world evidence now plays in informing clinical guidelines and securing new indications for approved medicines. We will also consider the novel coronavirus’ effect on the traditional clinical trial model and how real-world evidence could evolve as an important tool for drugmakers and regulators as research adapts to a new reality.